<DOC>
	<DOCNO>NCT01543178</DOCNO>
	<brief_summary>This study evaluate effectiveness safety repeat treatment rifaximin 550 mg three time day patient IBS diarrhea respond initial treatment rifaximin 550 mg three time day .</brief_summary>
	<brief_title>Irritable Bowel Syndrome With Diarrhea ( IBS-D ) Rifaximin Re-Treatment Study</brief_title>
	<detailed_description>It important chronic condition information product intend short course administration order confer prolonged benefit administer beyond first cycle use symptom reappear . This Phase 3 study evaluate efficacy safety repeat treatment rifaximin 550 mg three time daily ( TID ) 14 day subject IBS-D respond initial treatment course rifaximin 550 mg TID 14 day . This study consist several treatment phase outline : Screening/Treatment 1 Phase . Subjects receive single-blind placebo TID 7-13 day answer daily IBS symptom-related question . Treatment 2 Phase . Eligible subject receive open-label rifaximin 550 mg TID 2 week 4-week treatment-free follow-up . Responders continue Maintenance Phase 1 . Nonresponders withdraw study . Maintenance Phase 1 . Subjects continue treatment-free follow-up period 18 week either : 1 ) experience recurrence 2 ) enrollment meet Treatment 3 Phase ( Double Blind Repeat Treatment Phase ) . Subjects meet recurrence criterion end Maintenance Phase 1 withdraw study . Treatment 3 Phase/ Double Blind Repeat Treatment Phase . Subjects meet criterion recurrence randomize 1:1 receive either rifaximin 550 mg TID placebo TID 2 week 4-week treatment-free follow-up . Primary efficacy analysis perform end Treatment 3 Phase ( Week 6 double-blind period ) . Maintenance Phase 2 . All subject continue additional treatment-free follow-up period 6 week ( Maintenance Phase 2 ) . Treatment 4 Phase/Second Repeat Treatment Phase . Subjects receive double-blind treatment previously assign Treatment 3 Phase 2 week 4-week treatment-free follow-up . A lactulose breath test sub-study conduct select site .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>IBS confirm Rome III diagnostic criterion . At least 18 year age . Colonoscopy within past 10 year rule inflammatory bowel disease ; flexible sigmoidoscopy &lt; 50 year age previous colonoscopy &gt; 10 year prior . Willing maintain stable diet . include vitamin , supplement , nutraceuticals . Diabetes ( Type 1 2 ) . Lactose intolerance control lactosefree diet . Pregnant plan become pregnant lactating . History HIV hepatitis B C. Participation investigational study within past 30 day . Taking rifaximin antibiotic within past 60 day . Unstable cardiovascular pulmonary disease , change treatment last 30 day due worsen disease condition . History GI surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>IBS</keyword>
	<keyword>IBS-D</keyword>
	<keyword>IBS diarrhea</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Irritable bowel syndrome diarrhea</keyword>
</DOC>